 | | Vol. 12.03 – 26 January, 2023 |
| |
|
|
| Using a genetic model to delete Ezh2 in KRAS-driven lung adenocarcinomas, investigators observed that Ezh2 haploinsufficient tumors were less lethal and lower grade than Ezh2 fully-insufficient tumors, which were poorly differentiated and metastatic.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers investigated the potential role of GATA6 as a novel regulator of tracheal fibrosis. It was found that GATA6 and α-smooth muscle actin were obviously increased in tracheal fibrotic granulations and in TGFβ1-treated primary tracheal fibroblasts.
[Cellular Signalling] |
|
|
|
| An in vivo model of radiation-induced lung injury and in vitro conditioned culture model was constructed to evaluate the effect of NLRP3/interleukin-1β on fibroblasts activation.
[Respiratory Research] |
|
|
|
| The protective roles and mechanisms of Astaxanthin, a natural compound, in inflammatory injured lung epithelial cells were investigated.
[Experimental Biology And Medicine] |
|
|
|
| Scientists demonstrated that the release of IL-27, MCP-1, and TNF-α from BEAS-2B cells was upregulated upon stimulation by conidia, while the mitogen-activated protein kinase signaling pathway was activated.
[Scientific Reports] |
| |
|
|
| Researchers identified a critical role of the IKK/NF-κB signaling pathway in SCLC development. They revealed that IKK/NF-κB signaling played an important role in promoting SCLC, identifying the IKK/NF-κB pathway as a promising therapeutic target.
[Cell Death & Differentiation] |
|
|
|
| Investigators isolated epithelial cells from the human lung or mammary gland and investigated their response to irreparable DNA damage and to mitotic checkpoints.
[Cell Death Discovery] |
|
|
|
| Scientists demonstrated that epithelial-to-mesenchymal transition-induced protein changes in small extracellular vesicles were detectable in NSCLC patients and had prognostic significance.
[Communications Biology] |
|
|
|
| Researchers found that KU60019, a novel, and highly specific ATM kinase inhibitor interfered with the association of ATM with type II topoisomerases (TOP2) β and stabilized TOP2β-DNA cleavage complex, thereby impairing the repair of double-strand breaks, leading to accelerated cell death.
[Scientific Reports] |
|
|
|
|
| The authors discuss the effects of oncogenic driver mutations on the efficacy of immune-checkpoint inhibitors and the immune tumor microenvironment, as well as the potential vulnerabilities that could be exploited to overcome the challenges of immunotherapy for oncogene-addicted NSCLC.
[Nature Reviews Clinical Oncology] |
|
|
|
|
| Pliant Therapeutics, Inc. announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase IIa clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
[Pliant Therapeutics, Inc.] |
|
|
|
| Avalo Therapeutics, Inc. announced the completion of enrollment of the 80 patients targeted for the Phase II PEAK Trial evaluating AVTX-002 in patients with non-eosinophilic asthma.
[Avalo Therapeutics, Inc.] |
|
|
|
|
| February 13 – 16, 2023
Breckenridge, Colorado, United States |
|
|
|
|
|
| | Karolinska Institutet – Stockholm, Sweden |
|
|
|
| | STEMCELL Technologies – Vancouver, British Columbia, Canada |
|
|
|
| | IRCCS Candiolo Cancer Institute – Turin, Italy |
|
|
|
| | Pompeu Fabra University – Barcelona, Spain |
|
|
|
| | Shanghai Clinical Research and Trial Center – Shanghai, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
